{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:57Z","timestamp":1793338437233,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115314","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:15:45Z","timestamp":1788016545000},"page":"115314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Challenges and approaches to the design of hydrophilic linkers for antibody-drug conjugates"],"prefix":"10.1016","volume":"399","author":[{"given":"Xingquan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson Yiu-Nam","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115314_bb0005","series-title":"The Collected Papers of Paul Ehrlich","first-page":"106","article-title":"Experimental research on specific therapy","author":"Ehrlich","year":"1960"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0010","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1841393","article-title":"Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death","volume":"9","author":"Gomes-da-Silva","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0020","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugate for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115314_bb0025","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic veno-occlusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115314_bb0030","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115314_bb0035","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1471-4892(03)00083-3","article-title":"Antibody-targeted chemotherapy with immunoconjugates of calicheamicin","volume":"3","author":"Damle","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115314_bb0045","series-title":"Chemical Linkers in Antibody-Drug Conjugates (ADCs)","first-page":"377","article-title":"Enhancing the polarity of the linker-drug in ADCs","author":"Hoogenboom","year":"2021"},{"issue":"15","key":"10.1016\/j.jconrel.2026.115314_bb0050","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2026.115314_bb0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cbpa.2015.08.005","article-title":"An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety","volume":"28","author":"Drake","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115314_bb0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","article-title":"New developments for antibody-drug conjugate-based therapeutic approaches","volume":"40","author":"de Goeij","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"20","key":"10.1016\/j.jconrel.2026.115314_bb0065","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115314_bb0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1021\/acs.bioconjchem.6b00530","article-title":"Investigation of hydrophilic auristatin derivatives for use in antibody-drug conjugates","volume":"28","author":"Mendelsohn","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody-drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115314_bb0080","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0085","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A new class of antibody-drug conjugates with potent DNA alkylating activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115314_bb0090","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115314_bb0095","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1073\/pnas.1321237111","article-title":"A general approach to site-specific antibody-drug conjugates","volume":"111","author":"Tian","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0100","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0105","article-title":"Site-specific modification of native IgGs with flexible drug load","volume":"26","author":"Wehrm\u00fcller","year":"2025","journal-title":"ChemBioChem"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115314_bb0110","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115314_bb0115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","article-title":"IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a PEGylated glucuronide-monomethyl auristatin E linker for antibody-drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115314_bb0125","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1021\/acs.bioconjchem.9b00713","article-title":"Hydrophilic sequence-defined cross-linkers for antibody-drug conjugates","volume":"30","author":"Walker","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115314_bb0130","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0135","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.jconrel.2026.115314_bb0140","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.jconrel.2026.115314_bb0145","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1016\/j.bmcl.2016.08.082","article-title":"Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology","volume":"26","author":"Ogitani","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115314_bb0150","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"issue":"14","key":"10.1016\/j.jconrel.2026.115314_bb0155","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1039\/C9SC00285E","article-title":"Monodisperse polysarcosine-based highly loaded antibody-drug conjugates","volume":"10","author":"Viricel","year":"2019","journal-title":"Chem. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115314_bb0160","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat. Biotechnol."},{"issue":"41","key":"10.1016\/j.jconrel.2026.115314_bb0165","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent advances in half-life extension strategies for therapeutic peptides and proteins","volume":"24","author":"Tan","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2026.115314_bb0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","article-title":"Extension of in vivo half-life of biologically active molecules by XTEN protein polymers","volume":"240","author":"Podust","year":"2016","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115314_bb0175","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.bmc.2017.09.016","article-title":"Prospects of PASylation\u00ae for the design of protein and peptide therapeutics with extended half-life and enhanced action","volume":"26","author":"Gebauer","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"16","key":"10.1016\/j.jconrel.2026.115314_bb0180","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1158\/0008-5472.CAN-15-0129","article-title":"A polymer-based antibody-vinca drug conjugate platform: characterization and preclinical efficacy","volume":"75","author":"Yurkovetskiy","year":"2015","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115314_bb0185","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/jm2002958","article-title":"Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates","volume":"54","author":"Zhao","year":"2011","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115314_bb0190","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"Pt B","key":"10.1016\/j.jconrel.2026.115314_bb0195","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jconrel.2015.09.032","article-title":"Stabilization of cysteine-linked antibody-drug conjugates with N-aryl maleimides","volume":"220","author":"Christie","year":"2015","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115314_bb0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/acsptsci.3c00269","article-title":"Peptide-drug conjugates: design, chemistry, and drug delivery system as novel cancer theranostic","volume":"7","author":"Rizvi","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115314_bb0205","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"issue":"70","key":"10.1016\/j.jconrel.2026.115314_bb0210","doi-asserted-by":"crossref","first-page":"15867","DOI":"10.1002\/chem.202003951","article-title":"Improving the stability of maleimide-thiol conjugation for drug targeting","volume":"26","author":"Lahnsteiner","year":"2020","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.jconrel.2026.115314_bb0215","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoirs for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115314_bb0220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2024.08.049","article-title":"Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates","volume":"375","author":"Tedeschini","year":"2024","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0225","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115314_bb0230","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"21","key":"10.1016\/j.jconrel.2026.115314_bb0235","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm800719t","article-title":"Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy","volume":"51","author":"Moon","year":"2008","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.jconrel.2026.115314_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500305","article-title":"Advanced antibody-drug conjugates design: innovation in linker chemistry and site-specific conjugation technologies","volume":"26","author":"Matsuda","year":"2025","journal-title":"ChemBioChem"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115314_bb0245","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/acs.bioconjchem.3c00374","article-title":"The evolving landscape of antibody-drug conjugates: in-depth analysis of recent research progress","volume":"34","author":"Sasso","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115314_bb0250","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115314_bb0255","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115314_bb0260","first-page":"12","article-title":"Optimization of linker chemistries for antibody-drug conjugates","volume":"36","author":"Challener","year":"2023","journal-title":"BioPharm. Int."},{"key":"10.1016\/j.jconrel.2026.115314_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.764540","article-title":"Incorporation of hydrophilic macrocycles into drug-linker reagents produces antibody-drug conjugates with enhanced in vivo performance","volume":"13","author":"Evans","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115314_bb0270","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115314_bb0275","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"15","key":"10.1016\/j.jconrel.2026.115314_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: a comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115314_bb0285","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1021\/acs.molpharmaceut.9b00696","article-title":"Optimizing lysosomal activation of antibody-drug conjugates by incorporation of novel cleavable dipeptide linkers","volume":"16","author":"Salomon","year":"2019","journal-title":"Mol. Pharm."},{"issue":"20","key":"10.1016\/j.jconrel.2026.115314_bb0290","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115314_bb0295","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115314_bb0300","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1039\/D3MD00569K","article-title":"Linker substitution influences succinimide ring hydrolysis equilibrium impacting the stability of attachment to antibody-drug conjugates","volume":"15","author":"Wang","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"39","key":"10.1016\/j.jconrel.2026.115314_bb0305","doi-asserted-by":"crossref","first-page":"13841","DOI":"10.1021\/acs.langmuir.3c01294","article-title":"Reduction-responsive cationic vesicles from amphiphiles with ionizable amino acid or dipeptide polar heads","volume":"39","author":"Bernal-Mart\u00ednez","year":"2023","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2026.115314_bb0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-2272-7_3","article-title":"Getting across the cell membrane: an overview for small molecules, peptides, and proteins","volume":"1266","author":"Yang","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0315","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115314_bb0320","article-title":"Crossing biological barriers: recent advances in nanotechnology for cytosolic protein drug delivery systems","volume":"2","author":"Zhu","year":"2025","journal-title":"Precis. Med. Eng."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115314_bb0325","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1021\/cbe.4c00168","article-title":"Mechanistic insights into the tools for intracellular protein delivery","volume":"2","author":"Xie","year":"2024","journal-title":"Chem. Bio. Eng."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115314_bb0330","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ph15101283","article-title":"Strategies for improving peptide stability and delivery","volume":"15","author":"Al Musaimi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115314_bb0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"Pt A","key":"10.1016\/j.jconrel.2026.115314_bb0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jconrel.2015.09.058","article-title":"Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates","volume":"220","author":"Yao","year":"2015","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115314_bb0345","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cancers11070957","article-title":"Novel silyl ether-based acid-cleavable antibody-MMAE conjugates with appropriate stability and efficacy","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.jconrel.2026.115314_bb0350","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.jconrel.2026.115314_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202202187","article-title":"Modular access to diverse chemiluminescent dioxetane-luminophores through convergent synthesis","volume":"61","author":"Gnaim","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115314_bb0360","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acs.bioconjchem.6b00337","article-title":"Novel cathepsin-cleavable triglycine linkers for maytansinoid antibody-drug conjugates","volume":"27","author":"Kern","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"46","key":"10.1016\/j.jconrel.2026.115314_bb0365","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1002\/anie.201204935","article-title":"The first generation of \u03b2-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy","volume":"51","author":"Legigan","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115314_bb0370","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/jacs.5b12547","article-title":"Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates","volume":"138","author":"Kern","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115314_bb0375","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1039\/C9SC06410A","article-title":"Sulfatase-cleavable linkers for antibody-drug conjugates","volume":"11","author":"Bargh","year":"2020","journal-title":"Chem. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115314_bb0380","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acscentsci.7b00026","article-title":"In vivo activation of duocarmycin\u2013antibody conjugates by near-infrared light","volume":"3","author":"Nani","year":"2017","journal-title":"ACS Cent. Sci."},{"issue":"46","key":"10.1016\/j.jconrel.2026.115314_bb0385","doi-asserted-by":"crossref","first-page":"13635","DOI":"10.1002\/anie.201507391","article-title":"Near-IR light-mediated cleavage of antibody-drug conjugates using cyanine photocages","volume":"54","author":"Nani","year":"2015","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"39","key":"10.1016\/j.jconrel.2026.115314_bb0390","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1039\/C9SC03016F","article-title":"A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates","volume":"10","author":"Zang","year":"2019","journal-title":"Chem. Sci."},{"issue":"33","key":"10.1016\/j.jconrel.2026.115314_bb0395","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1002\/anie.201800402","article-title":"Click-to-release chemistry for activation of bioorthogonal prodrugs","volume":"57","author":"Versteegen","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"26","key":"10.1016\/j.jconrel.2026.115314_bb0400","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1002\/anie.201500088","article-title":"Self-immolative spacers: kinetic aspects, structure-property relationships, and applications","volume":"54","author":"Alouane","year":"2015","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0405","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115314_bb0410","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of \u03b2-glucuronide linkers for monoclonal antibody-drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115314_bb0415","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1021\/bc9001097","article-title":"Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues","volume":"20","author":"Burke","year":"2009","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115314_bb0420","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acs.bioconjchem.1c00029","article-title":"Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates","volume":"32","author":"Chuprakov","year":"2021","journal-title":"Bioconjug. Chem."},{"issue":"17","key":"10.1016\/j.jconrel.2026.115314_bb0425","doi-asserted-by":"crossref","first-page":"18099","DOI":"10.1021\/acs.jmedchem.5c01500","article-title":"Recent advances in peptide linkers of antibody-drug conjugates","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115314_bb0430","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1535-7163.MCT-16-0038","article-title":"Development of novel quaternary ammonium linkers for antibody-drug conjugates","volume":"15","author":"Burke","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2026.115314_bb0435","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2023-174064","article-title":"IKS03, a novel CD19-targeted antibody-drug conjugate, induces target-dependent in vivo cell killing of B-cell lymphoma xenografts by DNA crosslinking","volume":"142","author":"Deckert","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.jconrel.2026.115314_bb0440","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2024.42.16_suppl.3023","article-title":"A phase 1a\/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas","volume":"42","author":"Lemech","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0445","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"issue":"40","key":"10.1016\/j.jconrel.2026.115314_bb0450","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1073\/pnas.1211023109","article-title":"Synthesis of site-specific antibody-drug conjugates using unnatural amino acids","volume":"109","author":"Axup","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.jconrel.2026.115314_bb0455","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1158\/1078-0432.CCR-25-1749","article-title":"Derivation of AZD5335, a novel FR\u03b1-targeted TOP1i-loaded ADC, for the treatment of FR\u03b1-expressing cancers","volume":"31","author":"Zoeller","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115314_bb0460","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/pharmaceutics14071378","article-title":"Peptide-based bioconjugates and therapeutics for targeted anticancer therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115314_bb0465","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","article-title":"Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates","volume":"26","author":"van Geel","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115314_bb0470","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115314_bb0475","series-title":"A new drug linker, a synthesis method thereof, and its use in drug conjugates","author":"Ma","year":"2025"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:25:03Z","timestamp":1793337903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":95,"alternative-id":["S0168365926007182"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115314","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and approaches to the design of hydrophilic linkers for antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115314"}}